Project description:An estimated 1% or less of the nanoparticles (NPs) deposited in lungs translocate to systemic circulation and enter other organs; however this estimation may not be accurate considering the low sensitivity of the existing in vivo NP detection methods. Moreover, the biological outcomes of such low levels of translocation are not elucidated. The objectives of the present study were to employ a Nano-scale Hyperspectral Microscope to spatially observe and spectrally profile NPs in tissues, and characterize the effects of NPs in blood, liver and heart following pulmonary deposition and subsequent translocation from lungs. Adult female C57BL/6 mice were exposed via intratracheal instillation to 18 and 162 µg per mouse of industrially relevant non-doped titanium dioxide nanoparticles (nano-TiO2). Using the Nano-scale Hyperspectral Microscope translocation to heart and liver was confirmed at both doses and to blood at the highest dose at 24 hours post-exposure time-point. The analysis of biological effects using DNA microarrays, RT-qPCR and ELISA revealed activation of complement cascade and inflammatory process in heart and specific activation of complement factor 3 in blood, potentially suggestive of activation of early innate immune response essential for particle opsonisation and clearance. The liver showed subtle response with changes in the expression of few genes associated with acute phase genes. This study establishes a direct link between particle translocation and systemic effects. An estimated 1% or less of the nanoparticles (NPs) deposited in lungs translocate to systemic circulation and enter other organs; however this estimation may not be accurate considering the low sensitivity of the existing in vivo NP detection methods. Moreover, the biological outcomes of such low levels of translocation are not elucidated. The objectives of the present study were to employ a Nano-scale Hyperspectral Microscope to spatially observe and spectrally profile NPs in tissues, and characterize the effects of NPs in blood, liver and heart following pulmonary deposition and subsequent translocation from lungs. Adult female C57BL/6 mice were exposed via intratracheal instillation to 18 and 162 µg per mouse of industrially relevant non-doped titanium dioxide nanoparticles (nano-TiO2). Using the Nano-scale Hyperspectral Microscope translocation to heart and liver was confirmed at both doses and to blood at the highest dose at 24 hours post-exposure time-point. The analysis of biological effects using DNA microarrays, RT-qPCR and ELISA revealed activation of complement cascade and inflammatory process in heart and specific activation of complement factor 3 in blood, potentially suggestive of activation of early innate immune response essential for particle opsonisation and clearance. The liver showed subtle response with changes in the expression of few genes associated with acute phase genes. This study establishes a direct link between particle translocation and systemic effects. This experiment consists of one dose of nano-TiO2 (162 ug) and one control. There are 2 time points for each treatment and control group, e.g., day 1 and day 28. Each dose or time point has 5-6 biological replicates. There are total 22 samples (arrays)

Project description:LRP1 and, in particular the region that spans the C-terminal half of domain CR9 (from Gly1127 to Cys1140), named LP3, is essential for aggregated LDL internalization and human coronary vascular smooth muscle cells (hcVSMC)-cholesterol loading. Here, we investigated whether LP3 and its retro-enantio version (DP3) are protective against sphingomyelinase (SMase) and phospholipase 2 (PLA2)-induced LDL aggregation, the structural basis underlying this protection and the impact that LRP1-derived peptides might have on hcVSMC-cholesterol loading and cholesterol-modulated signaling pathways. For this purpose, biochemical, biophysical, molecular, proteomic, and cellular experiments were performed. Turbidimetry measurements show that LP3 and DP3 inhibit LDL aggregation induced by SMase and PLA2 in a dose-dependent manner, although the efficacy of DP3 is higher. Gel filtration chromatography (GFC) and transmission electron microscopy (TEM) show that LP3, and more efficiently DP3, almost completely counteract the increased percentage of aggregated LDL induced by both SMase and PLA2, respectively. Native polyacrilamide gradient gel electrophoresis (GGE), agarose gel electrophoresis (AGE) and high-performance thin layer chromatography (HPTLC) partitioning of LDL phospholipids indicated that LP3 and DP3 prevent SMase-induced alterations in LDL size, electric charge and phospholipid content but not those induced by PLA2. In contrast, LP3 and DP3 show high efficacy to counteract changes in ApoB-100 conformation induced by both SMase and PLA2. Together, these results indicate that LRP1-derived peptides protect LDL against aggregation induced by SMase and PLA2 through a common mechanism based on their capacity to prevent ApoB-100 conformational changes. Proteomics and computational modeling methods suggest that LRP1 derived peptides are able to establish strong electrostatic interactions with a specific ApoB-100 basic region. TLC and confocal microscopy show that DP3 with higher efficacy than LP3 significantly reduce intracellular cholesteryl ester accumulation induced by SMase-LDL in hcVSMC. Moreover, proteomics studies evidence several signaling pathways modulated by SMase-LDL that are counteracted specifically by DP3. These findings demonstrate that LRP1 derivative peptides protect against LDL aggregation and preserve vascular cells against cholesterol loading and associated alterations in critical signal pathways

			Action	DRS
	151019_Q_Hela_01_01_1ug_50cm_CID_IT_EasySpray_90min_rep.msf	Msf
	151019_Q_Hela_01_01_1ug_50cm_CID_IT_EasySpray_90min_rep.pdResult	Other
	151019_Q_Hela_01_01_1ug_50cm_CID_IT_EasySpray_90min_rep.raw	Raw
	151019_Q_Hela_01_02_1ug_50cm_CID_IT_EasySpray_90min.raw	Raw
	151019_Q_Hela_01_03_1ug_50cm_CID_IT_EasySpray_90min.raw	Raw

Dataset Information

Performance of the Orbitrap Fusion Lumos Tribrid in single-shot analyses of human samples

Dataset's files

Publications

Evaluation of different peptide fragmentation types and mass analyzers in data-dependent methods using an Orbitrap Fusion Lumos Tribrid mass spectrometer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets